Cargando…

A Single Nucleotide Polymorphism in the Phospholipase D1 Gene is Associated with Risk of Non-Small Cell Lung Cancer

Phospholipase D (PLD) has an important role in various biological functions including vesicular transport, endocytosis, exocytosis, cell migration, and mitosis. These cellular biological processes are deregulated in the development of various human tumors. In order to explore the relationship betwee...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ahn, Myung-Ju, Park, Shin-Young, Kim, Won Kyu, Cho, Ju Hwan, Chang, Brian Junho, Kim, Dong Jo, Ahn, Jin Seok, Park, Keunchil, Han, Joong-Soo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Master Publishing Group 2012
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3614861/ https://www.ncbi.nlm.nih.gov/pubmed/23675264

Ejemplares similares

Prognostic and Predictive Value of KRAS Mutations in Advanced Non-Small Cell Lung Cancer
por: Sun, Jong-Mu, et al.
Publicado: (2013)

Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
por: Kim, Youjin, et al.
Publicado: (2019)

The Effectiveness of Maintenance Pharmacotherapies for Non-Small Cell Lung Cancer
por: Ahn, Myung-Ju, et al.
Publicado: (2012)

Phospholipase D and Its Essential Role in Cancer
por: Cho, Ju Hwan, et al.
Publicado: (2017)

Prognostic value of volumetric metabolic parameters measured by [(18)F]Fluorodeoxyglucose-positron emission tomography/computed tomography in patients with small cell lung cancer
por: Park, Soo Bin, et al.
Publicado: (2014)

Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis
por: Byeon, Seonggyu, et al.
Publicado: (2016)

Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases
por: Ahn, Soomin, et al.
Publicado: (2016)

Predictive and Prognostic Value of (18)F-fluorodeoxyglucose Uptake Combined with Thymidylate Synthase Expression in Patients with Advanced Non-Small Cell Lung Cancer
por: Moon, Seung Hwan, et al.
Publicado: (2019)

Long-term Survival in Non–Small Cell Lung Cancer Patients with Metachronous Brain-Only Oligorecurrence Who Underwent Definitive Treatment
por: Kim, Hongsik, et al.
Publicado: (2022)

Comprehensive evaluation of the clinical utility of plasma EGFR test in non-small cell lung cancer patients with acquired resistance to first-line EGFR inhibitors
por: Kim, Hongsik, et al.
Publicado: (2021)

Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer
por: Park, Silvia, et al.
Publicado: (2015)

Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: Are They Different from Those with Common EGFR Mutations?
por: Jung, Hyun Ae, et al.
Publicado: (2020)

Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A Post Hoc Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial
por: Kang, Jin Hyoung, et al.
Publicado: (2016)

PD‐1 inhibitors for non‐small cell lung cancer patients with special issues: Real‐world evidence
por: Byeon, Seonggyu, et al.
Publicado: (2020)

Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea
por: Byeon, Seonggyu, et al.
Publicado: (2019)

Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea
por: Lee, Kangkook, et al.
Publicado: (2020)

ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non‐small cell lung cancer
por: Ku, Bo Mi, et al.
Publicado: (2022)

Molecularly Targeted Therapy Using Bevacizumab for Non-Small Cell Lung Cancer: a Pilot Study for the New CT Response Criteria
por: Lee, Ho Yun, et al.
Publicado: (2010)

High Dose Involved Field Radiation Therapy as Salvage for Loco-Regional Recurrence of Non-Small Cell Lung Cancer
por: Bae, Sun Hyun, et al.
Publicado: (2012)

Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer
por: Lee, Jiyun, et al.
Publicado: (2019)

Expanded Access Program Pralsetinib in Advanced Non–Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement
por: Jeon, Youngkyung, et al.
Publicado: (2023)

Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs
por: Kim, Kyung Hwan, et al.
Publicado: (2020)

EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
por: Park, Sehhoon, et al.
Publicado: (2020)

Tumor infiltrated immune cell types support distinct immune checkpoint inhibitor outcomes in patients with advanced non‐small cell lung cancer
por: Ku, Bo Mi, et al.
Publicado: (2021)

Role of Adjuvant Thoracic Radiation Therapy and Full Dose Chemotherapy in pN2 Non-small Cell Lung Cancer: Elucidation Based on Single Institute Experience
por: Park, Hyojung, et al.
Publicado: (2017)

The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer
por: Jung, Hyun Ae, et al.
Publicado: (2020)

Definitive Bimodality Concurrent Chemoradiotherapy in Patients with Inoperable N2-positive Stage IIIA Non-small Cell Lung Cancer
por: Noh, Jae Myoung, et al.
Publicado: (2015)

Adjuvant therapy in stage IIIA-N2 non-small cell lung cancer after neoadjuvant concurrent chemoradiotherapy followed by surgery
por: Shin, Sumin, et al.
Publicado: (2020)

Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer
por: Ku, Bo Mi, et al.
Publicado: (2019)

Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer?
por: Lee, Jiyun, et al.
Publicado: (2020)

Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer
por: Ku, Bo Mi, et al.
Publicado: (2017)

Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study
por: Lee, Ji Hyun, et al.
Publicado: (2016)

Dual-Energy CT in Patients Treated with Anti-Angiogenic Agents for Non-Small Cell Lung Cancer: New Method of Monitoring Tumor Response?
por: Kim, Yoo Na, et al.
Publicado: (2012)

Single-nucleotide polymorphism-based epidemiological analysis of Korean Mycobacterium bovis isolates
por: Kim, Tae-Woon, et al.
Publicado: (2021)

Molecular subtypes of small cell lung cancer transformed from adenocarcinoma after EGFR tyrosine kinase inhibitor treatment
por: Hwang, Soohyun, et al.
Publicado: (2021)

Salvage Concurrent Chemo-radiation Therapy for Loco-regional Recurrence Following Curative Surgery of Non-small Cell Lung Cancer
por: Lee, Kyung Hwa, et al.
Publicado: (2019)

Trends in Survival Rates of Non–Small Cell Lung Cancer With Use of Molecular Testing and Targeted Therapy in Korea, 2010-2020
por: Chi, Sang Ah, et al.
Publicado: (2023)

Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment
por: Kim, Kyung Hwan, et al.
Publicado: (2020)

Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Kim, Hana, et al.
Publicado: (2023)

Metabolic radiogenomics in lung cancer: associations between FDG PET image features and oncogenic signaling pathway alterations
por: Kim, Gahyun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0hgimotnsf0ocjliauds3lj7cm